Vemurafenib acts as a molecular on-off switch governing systemic inflammation in Langerhans cell histiocytosis

Langerhans cell histiocytosis (LCH) is a neoplasm marked by the accumulation of CD1A(+)CD207(+) cells. It is most commonly driven by a somatic, activating mutation in the BRAF serine-threonine kinase (BRAF(V600E)). Multisystem disease with risk-organ involvement requires myelotoxic chemotherapy, mak...

Descripción completa

Detalles Bibliográficos
Autores principales: Eder, Sebastian K., Schwentner, Raphaela, Ben Soussia, Philipp, Abagnale, Giulio, Attarbaschi, Andishe, Minkov, Milen, Halbritter, Florian, Hutter, Caroline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Stimulus Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945316/
https://www.ncbi.nlm.nih.gov/pubmed/34619771
http://dx.doi.org/10.1182/bloodadvances.2021005442

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945316/
https://www.ncbi.nlm.nih.gov/pubmed/34619771
http://dx.doi.org/10.1182/bloodadvances.2021005442

Ejemplares similares